PerkinElmer Launches First Cell Painting Kit
PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today launched the first cell painting kit as part of its new portfolio of PhenoVue™ cellular imaging reagents . This new range of reagents leverages PerkinElmer’s expertise in cellular imaging and high-content screening and works alongside the Company’s microplates, automation, software and industry-leading high-content screening instruments. With this entire screening workflow, researchers can better understand disease and develop more pinpointed therapies and drugs to treat them.
Cell painting is a powerful application of high-content screening technology which combines cell and computational biology to study the effects of perturbagens such as chemical compounds, drugs or genes on the behavior of cells. Cells are “painted” by labelling cellular compartments with different fluorescent bioprobes to enable those areas to be quantitatively profiled. However, preparing reagents from scratch can be incredibly time consuming.
Helping to address this challenge, the PhenoVue™ cell painting kit provides convenience and simplicity through a ready-to-use format and is part of a new range of reagents that also includes fluorescent organelle staining probes and dye-labelled secondary antibodies. These reagents are validated for high-content screening applications to reduce customers’ assay development time. For example, customers can use these reagents with PerkinElmer’s CellCarrier™ Ultra microplates, the PerkinElmer Opera Phenix® Plus high-content screening system, Operetta CLS™ high-content analysis system and Harmony® high-content analysis software.
“Researchers are using high-content screening and cell painting to make extraordinary discoveries that will help drive more innovative drugs and therapies,” said Alan Fletcher, Vice President and GM of Life Sciences, PerkinElmer. “With the addition of our new PhenoVue™ cellular imaging reagents, we now offer a complete suite of high-content screening products and expert services. This will help researchers build more streamlined workflows and enjoy the convenience of working with a single, expert technology provider helping to accelerate discovery.”
For more information on PerkinElmer’s new PhenoVue cellular imaging reagents, please visit www.perkinelmer.com/PhenoVue .
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-C3.AI/BAKER-HUGHES26.2.2021 15:02:05 CET | Press release
C3 AI and Baker Hughes to Provide Enterprise AI Solutions to Accelerate PETRONAS Digital Transformation Program
AVANIA26.2.2021 14:02:10 CET | Press release
Avania in Position for Next Stage of Growth
IPSEN26.2.2021 12:39:07 CET | Press release
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma
CA-ANDERSEN-GLOBAL26.2.2021 11:53:13 CET | Pressemeddelelse
Andersen Global styrker sin caribiske platform med Baptiste & Co. Law Firm
HIRO-CAPITAL26.2.2021 09:57:10 CET | Press release
Hiro Capital Leads $15 Million of Games VC Investment Into Snowprint Studios, Double Loop Games and Happy Volcano Games
INSPUR-INFORMATION26.2.2021 09:09:06 CET | Press release
Inspur Information Releases 2020 Global Computing Index Report
DE-INCYTE26.2.2021 09:02:05 CET | Press release
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom